1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Unresectable Gastric Carcinoma: new trials by email Literature Review of Unresectable Gastric Carcinoma trials Research Report on Unresectable Gastric Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) Disitamab Vedotin, Sintilimab, S-1 - HER2-positive Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 110 | 2024-10-17 | 2026-09-15 |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Olaparib, Ramucirumab - Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2018-02-06 | 2026-02-03 |
Stomach Neoplasms (3) · Esophageal Neoplasms (2) · Adenocarcinoma Of Esophagus (1)
Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Stomach Diseases (3) · Esophageal Diseases (2) · Head and Neck Neoplasms (2)
Ramucirumab (2) · Capecitabine (1) · Cisplatin (1) · Fluorouracil (1) · Oxaliplatin (1) · Paclitaxel (1) · S 1 (combination) (1) · Trastuzumab (1) · balstilimab (1) · disitamab vedotin (1) · olaparib (1) · sintilimab (1)
Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Qilu Hospital of Shandong University (1)
United States (2) · China (1)
Lian Liu, MD (1) · Michael Cecchini (1) · Yelena Janjigian, MD (1)
UM1CA186689 (1)